Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer, has announced their Annual General Meeting (AGM) for shareholders on June 24, 2024, at the offices of Shakespeare Martineau LLP in London. The company, which is pioneering a blood test for the early detection of lung cancer through a stable plasma biomarker called CIZ1B, has made the AGM details available on their website. Cizzle Biotechnology’s innovation stems from research by Professor Coverley and colleagues at the University of York.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
